Program By Day

7:00 AM-6:15 PM Exhibits Open
7:00 AM-7:45 AM Complimentary Continental Breakfast
7:45 AM-9:30 AM

Welcome and General Session 1: Diagnosis and Multimodality Treatment of Localized Disease (ARS)

Christopher J. Kane, MD—Chair
University of California, San Diego

Thomas J. Pugh, MD—Chair
University of Colorado

Daniel W. Lin, MD
University of Washington
Welcome

Case-Based Debate: Magnetic Resonance and Magnetic Resonance-Directed Biopsy: Where Is the Field Moving?

Christopher J. Kane, MD
University of California, San Diego
Moderator

Ivan Pedrosa, MD
The University of Texas Southwestern Medical Center
Radiologist

Mark Emberton, MD, FRCS, MBBS, BSc Hons
University College London
Urologist

Mary-Ellen Taplin, MD
Dana-Farber Cancer Institute
Newly Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials

Alberto Briganti, MD, PhD
Vita-Salute San Raffaele University, Urological Research Institute, IRCCS Ospedale San Raffaele
Adjuvant Radiotherapy and Chemotherapy in Node-Positive Disease

Case-Based Debate: Radiotherapy After Prostatectomy: Adjuvant Versus Early Salvage

Paul L. Nguyen, MD
Brigham and Women's Hospital, Dana-Farber Cancer Institute
Moderator

Christopher L. Amling, MD, FACS
Oregon Health & Science University
Adjuvant Advocate

William U. Shipley, MD, FACR, FASTRO
Massachusetts General Hospital, Harvard Medical School
Early-Salvage Advocate

 

Abstract 1: Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression ± zoledronate for locally advanced prostate cancer.
First Author: David John Joseph, MD, FRANZCP

Panel Question and Answer

9:30 AM-10:00 AM Break
10:00 AM-11:30 AM

General Session 2: Emerging Diagnostics and Therapies in Advanced Prostate Cancer

Himisha Beltran, MD—Chair
Weill Cornell Medical College

 

William L. Dahut, MD—Chair
National Cancer Institute
 

Padmanee Sharma, MD, PhD
The University of Texas MD Anderson Cancer Center
Emerging Immunotherapy Strategies for Castrate Resistant Prostate Cancer 


Felix Y. Feng, MD
University of California, San Francisco
Management of Oligometastatic Prostate Cancer From Imaging to Therapy

Kim N. Chi, MD, FRCPC
British Columbia Cancer Agency
Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality

Joe M. O'Sullivan, MD, FRCR
Queen's University Belfast
Molecular Therapies in Bone Metastases

 

Abstract 160: Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.
First Author: Andrew J. Armstrong, MD

Panel Question and Answer

11:30 AM-1:00 PM Poster Session A: Prostate Cancer
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session A: Prostate Cancer
With Complimentary Boxed Lunch
12:00 PM- 12:45 PM

Poster Walks

 

Felix Y. Feng, MD, BA
University of California, San Francisco

 

Christopher Sweeney, MBBS
Dana-Farber Cancer Institute

12:00 PM-1:00 PM Trainee and Early-Career Networking Luncheon
1:00 PM-2:30 PM

Oral Abstract Session A: Prostate Cancer

 

Karen E. Knudsen, PhD—Chair
Sidney Kimmel Cancer Center at Thomas Jefferson University

Thomas J. Pugh, MD—Chair
University of Colorado

Abstract 3: PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).
First Author: Maha Hussain, MD, FACP, FASCO

Abstract 161: SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Eric Jay Small, MD, FASCO

Philip W. Kantoff, MD
Department of Medicine, Memorial Sloan Kettering Cancer Center
Discussion

Abstract 162: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.
First Author: Nicholas David James, MBBS, PhD

Abstract 163: A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
First Author: Fatima Karzai, MD

Robert B. Montgomery, MD
University of Washington
Discussion

Panel Question and Answer

2:30 PM-3:15 PM Prostate Cancer: Keynote Lecture

Robert G. Bristow, MD, PhD
Manchester Cancer Research Centre
Germline and Somatic Mutational Landscape in Prostate Cancer: State of Knowledge and Implications for Practice
3:15 PM-3:45 PM Break
3:45 PM-5:15 PM

General Session 3: Moderated Debates on Controversial Topics in Prostate Cancer (ARS)

Justin E. Bekelman, MD—Chair
University of Pennsylvania

Francesco Montorsi, MD—Chair
Universita Vita Salute San Raffaele

Case-Based Debate: Is There Evidence for Local Treatment in Patients with Newly Diagnosed Metastatic Disease?

Elisabeth I. Heath, MD, FACP
Barbara Ann Karmanos Cancer Institute, Wayne State University
Moderator

Mack Roach III, MD, FASCO
University of California, San Francisco
Advocate

Adam Dicker, MD, PhD, FASTRO
The Sidney Kimmel Cancer Center at Thomas Jefferson University
Skeptic

Case-Based Debate: Abiraterone Versus Docetaxel

Nicholas J. Van As, MBBCH, MRCP, FRCR, MD(res)
The Royal Marsden Hospital
Moderator

Karim Fizazi, MD, PhD
Gustave Roussy, University of Paris Sud
Abiraterone Advocate

Christopher Sweeney, MBBS
Dana-Farber Cancer Institute
Docetaxel Advocate

 

Abstract 2: Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.
First Author: Daniel Eidelberg Spratt, MD

Panel Question and Answer

5:15 PM-6:15 PM

Rapid-Fire Abstract Session: Prostate Cancer

 

Paul L. Nguyen, MD - Chair
Birgham and Women's Hospital, Dana-Farber Cancer Institute

Abstract 4: Daily versus weekly prostate cancer image-guided radiotherapy: A phase 3, multicenter, randomized trial.
First Author: Renaud de Crevoisier, MD, PhD

Question and Answer

Abstract 5: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.
First Author: Ananya Choudhury, MA, PhD, MRCP, FRCR

Question and Answer

Abstract 164: Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study.
First Author: Rebeca Lozano, MD

Question and Answer

Abstract 165: The FALCON trial: Impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer.
First Author: Eugene Jueren Teoh, MBBS, MRCP

Question and Answer

5:15 PM-6:15 PM Poster Session A: Prostate Cancer, Continued
With Complimentary Wine and Cheese
5:15 PM-6:15 PM Trials in Progress Poster Session A: Prostate Cancer, Continued
With Complimentary Wine and Cheese